Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement
- Details
- Category: Boehringer Ingelheim
Pfēnex Inc., an industry leader in protein expression through the Pfēnex Expression Technology™ platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, have entered into a strategic agreement.
Lilly Marks Major Milestone for Mirror Portfolio
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that the Mirror Portfolio, a concept created by Lilly to access innovation being developed outside the company's walls, has achieved a significant milestone.
First African country introduces GSK's pneumococcal vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneumococcal vaccines through the innovative financing mechanism known as the Advance Market Commitment (AMC),
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement
- Details
- Category: Boehringer Ingelheim
Elan plc (NYSE: ELN) and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
Sanofi-aventis' fourth-quarter and full-year net sales
- Details
- Category: Sanofi
In the fourth quarter of 2010, sanofi-aventis generated net sales of €7,395 million, up 0.5% on a reported basis. Exchange rate movements had a favorable effect of 6.4 percentage points, mainly due to the weaker euro versus the U.S. dollar, Japanese Yen, Brazilian Real, and Australian dollar.
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
- Details
- Category: Novartis
The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].
More Pharma News ...
- FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
- Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
- GSK revises US Avandia label to include new restrictions on use
- Pfizer To Acquire Ferrosan's Consumer Healthcare Business
- Nycomed to acquire Colombian company Farmacol
- New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
- GSK's full year trading update